Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV)

In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata and non-segmental vitiligo, and strong Phase 3 lymphoma data for epcoritamab plus lenalidomide versus R-GemOx. Together, these updates extend AbbVie’s immunology and oncology reach into earlier-stage, high-need patient groups, potentially deepening usage of i…